Abbott Laboratories Announces Strong Q1 2025 Financial Results

Abbott Laboratories has reported a notable increase in its first-quarter revenue for 2025, marking a 4% rise to $10.4 billion compared to the previous year. The company's net earnings saw an 8.2% growth, reaching $1.3 billion, with diluted earnings per share (EPS) climbing 8.6% to $0.76.

CEO Highlights Diversified Business Model as Key to Success

According to CEO Robert Ford, Abbott's diversified business model is the cornerstone of its ability to deliver top-tier sales and EPS growth. "This diversification and execution enable Abbott to navigate through periods of uncertainty and continually deliver sustainable growth," Ford stated. The company has reaffirmed its 2025 guidance, projecting organic sales growth of 7.5% to 8.5%, an adjusted operating margin between 23.5% and 24.0% of sales, and adjusted diluted EPS ranging from $5.05 to $5.25.